Company profile SABS

SAB Biotherapeutics Inc
sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.
Quarter analysis & expected interestLast update: February 08 2024 01:07:23.

After 38 days of this quarter the interest is at 35.0. Based on that we can calculate that during remaining 53 days it will total up to 84.0.
SAB Biotherapeutics expected interest is significantly lower compared to previous quarter (-70.3%) but similar to same quarter last year.

YearQ1Q2Q3Q4
201940
118
195.0% QoQ
95
-19.5% QoQ
0
-100.0% QoQ
2020 257
542.5% YoY inf% QoQ
404
242.4% YoY 57.2% QoQ
210
121.1% YoY -48.0% QoQ
213
inf% YoY 1.4% QoQ
2021 200
-22.2% YoY -6.1% QoQ
112
-72.3% YoY -44.0% QoQ
196
-6.7% YoY 75.0% QoQ
430
101.9% YoY 119.4% QoQ
2022 258
29.0% YoY -40.0% QoQ
188
67.9% YoY -27.1% QoQ
139
-29.1% YoY -26.1% QoQ
330
-23.3% YoY 137.4% QoQ
2023 130
-49.6% YoY -60.6% QoQ
188
0.0% YoY 44.6% QoQ
96
-30.9% YoY -48.9% QoQ
283
-14.2% YoY 194.8% QoQ
2024 35
-73.1% YoY -87.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and SAB Biotherapeutics search interestLast update: February 08 2024 01:07:22.
Correlation coefficient between keyword and revenue is -0.48
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 01:07:24.

The average 5 years interest of SAB Biotherapeutics was 15.03 per week.
The last year interest of SAB Biotherapeutics compared to the last 5 years has changed by -20.83%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 98.33%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics news to provide analysis

Correlation between past revenue and SAB Biotherapeutics news search interest

There is not enough data for SAB Biotherapeutics news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 01:07:29.

After 38 days of this quarter the interest is at 41.0. Based on that we can calculate that during remaining 53 days it will total up to 98.0.
SAB Biotherapeutics stock price expected interest is significantly lower compared to same quarter last year (-49.5%) but similar to previous quarter.

YearQ1Q2Q3Q4
201994
82
-12.8% QoQ
95
15.9% QoQ
137
44.2% QoQ
2020 0
-100.0% YoY -100.0% QoQ
175
113.4% YoY inf% QoQ
0
-100.0% YoY -100.0% QoQ
86
-37.2% YoY inf% QoQ
2021 67
inf% YoY -22.1% QoQ
30
-82.9% YoY -55.2% QoQ
123
inf% YoY 310.0% QoQ
113
31.4% YoY -8.1% QoQ
2022 231
244.8% YoY 104.4% QoQ
85
183.3% YoY -63.2% QoQ
163
32.5% YoY 91.8% QoQ
144
27.4% YoY -11.7% QoQ
2023 194
-16.0% YoY 34.7% QoQ
0
-100.0% YoY -100.0% QoQ
144
-11.7% YoY inf% QoQ
83
-42.4% YoY -42.4% QoQ
2024 41
-78.9% YoY -50.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and SAB Biotherapeutics stock price search interestLast update: February 08 2024 01:07:29.
Correlation coefficient between keyword and revenue is 0.53
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 01:07:29.

The average 5 years interest of SAB Biotherapeutics stock price was 8.0 per week.
The last year interest of SAB Biotherapeutics stock price compared to the last 5 years has changed by -14.88%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -13.25%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics clinical trials to provide analysis

Correlation between past revenue and SAB Biotherapeutics clinical trials search interest

There is not enough data for SAB Biotherapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics immunotherapies to provide analysis

Correlation between past revenue and SAB Biotherapeutics immunotherapies search interest

There is not enough data for SAB Biotherapeutics immunotherapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics immunotherapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics COVID-19 treatment to provide analysis

Correlation between past revenue and SAB Biotherapeutics COVID-19 treatment search interest

There is not enough data for SAB Biotherapeutics COVID-19 treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics COVID-19 treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics influenza treatment to provide analysis

Correlation between past revenue and SAB Biotherapeutics influenza treatment search interest

There is not enough data for SAB Biotherapeutics influenza treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics influenza treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics autoimmune diseases to provide analysis

Correlation between past revenue and SAB Biotherapeutics autoimmune diseases search interest

There is not enough data for SAB Biotherapeutics autoimmune diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics autoimmune diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics DiversitAb immunotherapy platform to provide analysis

Correlation between past revenue and SAB Biotherapeutics DiversitAb immunotherapy platform search interest

There is not enough data for SAB Biotherapeutics DiversitAb immunotherapy platform to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics DiversitAb immunotherapy platform to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SAB Biotherapeutics human antibodies to provide analysis

Correlation between past revenue and SAB Biotherapeutics human antibodies search interest

There is not enough data for SAB Biotherapeutics human antibodies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SAB Biotherapeutics human antibodies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for SABS
Earnings date: 2024-03-29 After close
Company name: SAB Biotherapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T16:55:10Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10

2026-05-12T11:30:00Z

GlobeNewswire
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

2026-05-11T09:35:28Z

Analyst Upgrades
Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target

2026-05-05T12:30:00Z

GlobeNewswire
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

2026-04-29T11:35:00Z

GlobeNewswire
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

2026-04-22T11:00:00Z

GlobeNewswire
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

2026-04-15T12:00:00Z

GlobeNewswire
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

2026-03-10T11:55:01Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $7

2026-03-10T11:31:00Z

GlobeNewswire
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

2026-03-09T21:16:37Z

GlobeNewswire
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

2026-03-02T14:00:00Z

GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences

2026-02-04T14:00:00Z

GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences

2026-01-07T20:28:33Z

Analyst Upgrades
UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7

2026-01-07T13:00:00Z

GlobeNewswire
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

2025-12-19T14:04:47Z

Analyst Upgrades
Guggenheim Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $15